相似文献
1
Squamous cell carcinomas of the head and neck.
BMJ. 2002 Oct 12;325(7368):822-7. doi: 10.1136/bmj.325.7368.822.
2
Squamous cell carcinoma of the head and neck: past progress and future promise.
CA Cancer J Clin. 1998 Jul-Aug;48(4):195-8. doi: 10.3322/canjclin.48.4.195.
3
[Decision making in non resectable head and neck tumours].
Laryngorhinootologie. 2005 Mar;84(3):200-6; quiz 207-10. doi: 10.1055/s-2005-861132.
4
Optimizing approaches to head and neck cancer: strengths and weaknesses in multidisciplinary treatments of locally advanced disease.
Ann Oncol. 2008 Sep;19 Suppl 7:vii195-9. doi: 10.1093/annonc/mdn447.
5
An enhanced role for palliative care in the multidisciplinary approach to high-risk head and neck cancer.
Cancer. 2016 Feb 1;122(3):340-3. doi: 10.1002/cncr.29754. Epub 2015 Oct 27.
6
Cervical lymphatics and squamous cell carcinoma of the head and neck: biologic significance and therapeutic considerations.
Surg Oncol Clin N Am. 1996 Jan;5(1):65-77.
7
Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2010 May;21 Suppl 5:v184-6. doi: 10.1093/annonc/mdq185.
8
[Systemic therapy strategies for head-neck carcinomas: current status].
Laryngorhinootologie. 2012 Mar;91 Suppl 1:S123-43. doi: 10.1055/s-0031-1297244. Epub 2012 Mar 28.
9
Locally advanced head and neck cancer.
Curr Treat Options Oncol. 2001 Feb;2(1):7-13. doi: 10.1007/s11864-001-0012-x.
10
Clinical applications of DNA content parameters in patients with squamous cell carcinomas of the head and neck.
Semin Oncol. 1994 Jun;21(3):330-9.
引用本文的文献
1
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.
Future Oncol. 2025 Jul;21(16):2007-2016. doi: 10.1080/14796694.2025.2511470. Epub 2025 Jun 13.
2
Genomic and Single-Cell Analyses Characterize Patient-Derived Tumor Organoids to Enable Personalized Therapy for Head and Neck Squamous Cell Carcinoma.
Cancer Res. 2025 Apr 22. doi: 10.1158/0008-5472.CAN-24-2850.
3
dia-PASEF Proteomics of Tumor and Stroma LMD Enriched from Archived HNSCC Samples.
ACS Omega. 2025 Mar 25;10(13):13296-13302. doi: 10.1021/acsomega.4c11051. eCollection 2025 Apr 8.
4
Duchenne muscular dystrophy gene product expression is associated with survival in head and neck squamous cell carcinoma.
Sci Rep. 2025 Mar 28;15(1):10754. doi: 10.1038/s41598-025-94221-9.
5
Expression and prognostic significance of the m6A RNA methylation regulator HNRNPC in HNSCC.
Front Oncol. 2025 Feb 7;15:1516867. doi: 10.3389/fonc.2025.1516867. eCollection 2025.
6
The microRNA-6510 as a potential tumor suppressor in head and neck cancer.
Sci Rep. 2025 Feb 18;15(1):5830. doi: 10.1038/s41598-025-86796-0.
7
Advancements in prognostic factors and survival outcomes following pulmonary metastasectomy for head and neck cancers.
Kardiochir Torakochirurgia Pol. 2024 Dec;21(4):218-222. doi: 10.5114/kitp.2024.145835. Epub 2024 Dec 12.
8
dia-PASEF Proteomics of Tumor and Stroma LMD Enriched from Archived HNSCC Samples.
bioRxiv. 2024 Aug 10:2024.08.09.607341. doi: 10.1101/2024.08.09.607341.
9
Genomic and single-cell characterization of patient-derived tumor organoid models of head and neck squamous cell carcinoma.
bioRxiv. 2024 Jul 2:2024.06.28.601068. doi: 10.1101/2024.06.28.601068.
10
Tracing human papillomavirus in skin and mucosal squamous cell carcinoma: a histopathological retrospective survey.
Dermatol Reports. 2024 Feb 1;16(2):9833. doi: 10.4081/dr.2024.9833. eCollection 2024 Jun 14.
本文引用的文献
1
Concomitant chemoradiation for head and neck cancer: saving lives or grays?
Clin Oncol (R Coll Radiol). 2001;13(5):333-5. doi: 10.1053/clon.2001.9284.
2
Interventions for treating oral leukoplakia.
Cochrane Database Syst Rev. 2001(4):CD001829. doi: 10.1002/14651858.CD001829.
3
A prospective study of quality of life in head and neck cancer patients. Part II: Longitudinal data.
Laryngoscope. 2001 Aug;111(8):1440-52. doi: 10.1097/00005537-200108000-00022.
4
Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis.
Head Neck. 2001 Jul;23(7):579-89. doi: 10.1002/hed.1081.
5
A prospective study of quality of life in head and neck cancer patients. Part I: at diagnosis.
Laryngoscope. 2001 Apr;111(4 Pt 1):669-80. doi: 10.1097/00005537-200104000-00021.
6
Planned neck dissection for advanced primary head and neck malignancy treated with organ preservation therapy: disease control and survival outcomes.
Head Neck. 2001 Feb;23(2):73-9. doi: 10.1002/1097-0347(200102)23:2<73::aid-hed1001>3.0.co;2-6.
7
The burden of mouth cancer in Latin America and the Caribbean: epidemiologic issues.
Semin Oncol. 2001 Apr;28(2):158-68. doi: 10.1053/sonc.2001.21958.
8
Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG).
Ann Oncol. 2001 Feb;12(2):199-202. doi: 10.1023/a:1008322415335.
9
Organ preservation by transoral laser microsurgery in piriform sinus carcinoma.
Otolaryngol Head Neck Surg. 2001 Jan;124(1):58-67. doi: 10.1067/mhn.2001.111597.
10
Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.
Int J Hematol. 2000 Dec;72(4):425-35.
Zotero 插件